PARP14 is a novel target in STAT6 mutant follicular lymphoma

The variable clinical course of follicular lymphoma (FL) is determined by the molecular heterogeneity of tumor cells and complex interactions within the tumor microenvironment (TME). IL-4 producing follicular helper T cells (T(FH)) are critical components of the FL TME. Binding of IL-4 to IL-4R on FL cells activates JAK/STAT signaling. We identified STAT6 mutations (STAT6(MUT)) in 13% of FL (N = 33/258), all clustered within the DNA binding domain. Gene expression data and immunohistochemistry showed upregulation of IL-4/STAT6 target genes in STAT6(MUT) FL, including CCL17, CCL22, and FCER2 (CD23). Functionally, STAT6(MUT) was gain-of-function by serial replating phenotype in pre-B CFU assays. Expression of STAT6(MUT) enhanced IL-4 induced FCER2/CD23, CCL17 and CCL22 expression and was associated with nuclear accumulation of pSTAT6. RNA sequencing identified PARP14 -a transcriptional switch and co-activator of STAT6- among the top differentially upregulated genes in IL-4 stimulated STAT6(MUT) lymphoma cells and in STAT6(MUT) primary FL cells. Quantitative chromatin immunoprecipitation (qChIP) demonstrated binding of STAT6(MUT) but not STAT6(WT) to the PARP14 promotor. Reporter assays showed increased IL-4 induced transactivation activity of STAT6(MUT) at the PARP14 promotor, suggesting a self-reinforcing regulatory circuit. Knock-down of PARP14 or PARP-inhibition abrogated the STAT6(MUT) gain-of-function phenotype. Thus, our results identify PARP14 as a novel therapeutic target in STAT6(MUT) FL.